CPIX (Cumberland Pharmaceuticals Inc)
Insider Trading Activity
Every open-market purchase and sale reported by CPIX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-20 | Joseph C Galante | Director | A | — | — |
| 2026-03-20 | John M. Hamm | VP Chief Financial Officer | A | — | — |
| 2026-03-20 | Chris T. Bitterman | Vice Pres Sales & Marketing | A | — | — |
| 2026-03-20 | Todd M. Anthony | Vice Pres Organizational Dev | A | — | — |
| 2026-03-20 | James Jones | Director | A | — | — |
| 2026-03-20 | Martin S Brown JR | Director | A | — | — |
| 2026-03-20 | James L Herman | VP and Chief Compliance Office | A | — | — |
| 2026-03-20 | A J KAZIMI | Chairman and CEO | A | — | — |
| 2026-03-20 | Caroline Young | Director | A | — | — |
| 2026-03-20 | Kenneth Krogulski | Director | A | — | — |
| 2026-03-18 | A J KAZIMI | Chairman and CEO | F | — | — |
| 2026-01-06 | Kenneth Krogulski | Director | L | — | — |
| 2026-01-06 | James Jones | Director | L | — | — |
| 2026-01-06 | A J KAZIMI | Chairman and CEO | L | — | — |
| 2026-01-06 | Caroline Young | Director | L | — | — |
| 2025-12-01 | James Jones | Director | L | — | — |
| 2025-12-01 | A J KAZIMI | Chairman and CEO | L | — | — |
| 2025-12-01 | Caroline Young | Director | L | — | — |
| 2025-12-01 | Kenneth Krogulski | Director | L | — | — |
| 2025-11-03 | A J KAZIMI | Chairman and CEO | L | — | — |
| 2025-11-03 | Caroline Young | Director | L | — | — |
| 2025-11-03 | Kenneth Krogulski | Director | L | — | — |
| 2025-11-03 | James Jones | Director | L | — | — |
| 2025-10-03 | Caroline Young | Director | L | — | — |
| 2025-10-03 | Kenneth Krogulski | Director | L | — | — |
| 2025-10-03 | A J KAZIMI | Chairman and CEO | L | — | — |
| 2025-10-03 | James Jones | Director | L | — | — |
| 2025-09-12 | James Jones | Director | Buy | — | — |
| 2025-09-12 | A J KAZIMI | Chairman and CEO | Buy | — | — |
| 2025-09-12 | Kenneth Krogulski | Director | Buy | — | — |
| 2025-09-12 | Caroline Young | Director | Buy | — | — |
| 2025-08-11 | Kenneth Krogulski | Director | Buy | — | — |
| 2025-08-11 | Caroline Young | Director | Buy | — | — |
| 2025-08-11 | A J KAZIMI | Chairman and CEO | Buy | — | — |
| 2025-08-11 | James Jones | Director | Buy | — | — |
| 2025-07-11 | James Jones | Director | Buy | — | — |
| 2025-07-11 | A J KAZIMI | Chairman and CEO | Buy | — | — |
| 2025-07-11 | Kenneth Krogulski | Director | Buy | — | — |
| 2025-07-11 | Caroline Young | Director | Buy | — | — |
| 2025-06-06 | James Jones | Director | Buy | — | — |
| 2025-06-06 | A J KAZIMI | Chairman and CEO | Buy | — | — |
| 2025-06-06 | Caroline Young | Director | Buy | — | — |
| 2025-06-06 | Kenneth Krogulski | Director | Buy | — | — |
| 2025-05-09 | A J KAZIMI | Chairman and CEO | Buy | — | — |
| 2025-05-09 | James Jones | Director | Buy | — | — |
| 2025-05-09 | Caroline Young | Director | Buy | — | — |
| 2025-05-09 | Kenneth Krogulski | Director | Buy | — | — |
| 2025-04-04 | A J KAZIMI | Chairman and CEO | Buy | — | — |
| 2025-04-04 | Caroline Young | Director | Buy | — | — |
| 2025-04-04 | Kenneth Krogulski | Director | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chairman and CEO | 5,695,310 | — |
| — | Director | 583,344 | — |
| — | Sr. VP & Corp. Secretary | 440,828 | — |
| — | Director | 417,569 | — |
| — | Director | 302,338 | — |
| — | Director | 204,110 | — |
| — | Sr VP/Chief Commercial Officer | 163,473 | — |
| — | SVP and Chief Development Off. | 129,618 | — |
| — | Director | 98,415 | — |
| — | Director | 63,656 | — |
| — | Director | 46,863 | — |
| — | Chief Financial Officer | 45,000 | — |
| — | VP and Chief Compliance Office | 38,255 | — |
| — | Director | 35,109 | — |
| — | VP Chief Financial Officer | 20,073 | — |
| — | Vice Pres Organizational Dev | 16,328 | — |
| — | Director | 14,803 | — |
| — | Chief Financial Officer | 11,720 | — |
| — | Director | 10,300 | — |
| — | Vice Pres Sales & Marketing | 4,683 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CPIX quote page; the site-wide leaderboard is on the insider transactions hub.